Stereotaxis, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $142.3M
- Price
- $1.42
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.39%
- Volume
- 360.8K
About
Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.
Quick stats
Shares outstanding100.2M
Computed float65.8M
Float / shares65.6%
Key info
SectorHealthcare
IndustryMedical - Instruments & Supplies
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001289340
Websitehttps://www.stereotaxis.com
AI Summary
AI-generated1/14
standardmixedearnings
Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates
Stereotaxis reported Q2 revenue of $7.7 million, a decrease from the prior year, as system revenue dropped to $1.5 million while recurring revenue increased to $6.2 million.
The company highlighted a commercial inflection point with robotic catheter revenue surpassing $1 million, up 270% sequentially, alongside the first US purchase of a GenesisX system and sales of Synchrony systems.
Management guided for recurring revenue growth to approximately $7 million in Q3 and $8 million in Q4, anticipating cash flow profitability in the first half of 2027 while ending the quarter with $10.5 million in cash and no debt.
Red flags
- Total revenue declined year-over-year
- GAAP net loss widened to $4.5 million from $3.8 million in the prior year
- Cash balance of $10.5 million with negative free cash flow of $3.7 million in the quarter raises solvency concerns if targets are missed